{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T20:57:10Z","timestamp":1754600230505},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T00:00:00Z","timestamp":1524009600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Janssen-Cilag Pty Ltd","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s10067-018-4105-3","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T22:40:56Z","timestamp":1524004856000},"page":"1617-1623","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors"],"prefix":"10.1007","volume":"37","author":[{"given":"Kathleen","family":"Tymms","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoff","family":"Littlejohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hedley","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"de Jager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Bird","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Joshua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Nash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malcolm","family":"Handel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamish","family":"McManus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belinda E.","family":"Butcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,18]]},"reference":[{"issue":"9","key":"4105_CR1","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1136\/ard.2005.046367","volume":"65","author":"D Huscher","year":"2006","unstructured":"Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A, German Collaborative Arthritis C (2006) Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 65(9):1175\u20131183. https:\/\/doi.org\/10.1136\/ard.2005.046367","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4105_CR2","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman RD, Jongkees M, Khan MA, Kiltz U, Kvien T, Leirisalo-Repo M, Maksymowych WP, Olivieri I, Pavelka K, Sieper J, Stanislawska-Biernat E, Wendling D, Ozgocmen S, van Drogen C, van Royen B, van der Heijde D (2011) 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70(6):896\u2013904. https:\/\/doi.org\/10.1136\/ard.2011.151027","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4105_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","volume":"71","author":"L Gossec","year":"2012","unstructured":"Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, FitzGerald O, Aletaha D, Balint P, Boumpas D, Braun J, Breedveld FC, Burmester G, Canete JD, de Wit M, Dagfinrud H, de Vlam K, Dougados M, Helliwell P, Kavanaugh A, Kvien TK, Landewe R, Luger T, Maccarone M, McGonagle D, McHugh N, McInnes IB, Ritchlin C, Sieper J, Tak PP, Valesini G, Vencovsky J, Winthrop KL, Zink A, Emery P, European League Against R (2012) European league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 71(1):4\u201312. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200350","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4105_CR4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0889-857X(21)00171-X","volume":"19","author":"T Pincus","year":"1993","unstructured":"Pincus T, Callahan LF (1993) What is the natural history of rheumatoid arthritis? Rheum Dis Clin N Am 19(1):123\u2013151","journal-title":"Rheum Dis Clin N Am"},{"issue":"7","key":"4105_CR5","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00296-016-3423-5","volume":"36","author":"J Dalen","year":"2016","unstructured":"Dalen J, Svedbom A, Black CM, Lyu R, Ding Q, Sajjan S, Sazonov V, Kachroo S (2016) Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence. Rheumatol Int 36(7):987\u2013995. https:\/\/doi.org\/10.1007\/s00296-016-3423-5","journal-title":"Rheumatol Int"},{"issue":"6","key":"4105_CR6","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1185\/03007990902896386","volume":"25","author":"BJ Borah","year":"2009","unstructured":"Borah BJ, Huang X, Zarotsky V, Globe D (2009) Trends in RA patients\u2019 adherence to subcutaneous anti-TNF therapies and costs. Curr Med Res Opin 25(6):1365\u20131377. https:\/\/doi.org\/10.1185\/03007990902896386","journal-title":"Curr Med Res Opin"},{"issue":"6 Suppl","key":"4105_CR7","first-page":"S136","volume":"9","author":"CR Harley","year":"2003","unstructured":"Harley CR, Frytak JR, Tandon N (2003) Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 9(6 Suppl):S136\u2013S143","journal-title":"Am J Manag Care"},{"issue":"10","key":"4105_CR8","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1002\/art.24114","volume":"59","author":"S Curkendall","year":"2008","unstructured":"Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R (2008) Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum 59(10):1519\u20131526. https:\/\/doi.org\/10.1002\/art.24114","journal-title":"Arthritis Rheum"},{"issue":"10 Supl 2","key":"4105_CR9","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1097\/MLR.0b013e318041384c","volume":"45","author":"CG Grijalva","year":"2007","unstructured":"Grijalva CG, Chung CP, Arbogast PG, Stein CM, Mitchel EF Jr, Griffin MR (2007) Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care 45(10 Supl 2):S66\u2013S76. https:\/\/doi.org\/10.1097\/MLR.0b013e318041384c","journal-title":"Med Care"},{"issue":"5","key":"4105_CR10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.clinthera.2014.02.019","volume":"36","author":"J Tkacz","year":"2014","unstructured":"Tkacz J, Ellis L, Bolge SC, Meyer R, Brady BL, Ruetsch C (2014) Utilization and adherence patterns of subcutaneously administered anti-tumor necrosis factor treatment among rheumatoid arthritis patients. Clin Ther 36(5):737\u2013747. https:\/\/doi.org\/10.1016\/j.clinthera.2014.02.019","journal-title":"Clin Ther"},{"key":"4105_CR11","unstructured":"Tahami AA, 704 KH Real-life treatment persistence with golimumab, etanercept, and adalimumab in patients with rheumatoid arthritis in Canada. In: 28th International Conference on Pharmacoepidemiology and therapeutic risk management (ICPE). Barcelona, Spain, p 2012"},{"key":"4105_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1445-5994.2010.02466.x","volume":"41","author":"L Roberts","year":"2011","unstructured":"Roberts L, Arnold M, Bird P, Burnet S, De Jager J, Littlejohn G, Nicholls D, Tymms K, Zochling J, Griffiths H (2011) ARA-P39 Optimising patient outcomes in Australian rheumatology (OPAL)\u2014a quality use of medicines initiative (QUMI) with >7000 rheumatoid arthritis (RA) patients. Intern Med J 41:9\u201338. https:\/\/doi.org\/10.1111\/j.1445-5994.2010.02466.x","journal-title":"Intern Med J"},{"issue":"3","key":"4105_CR13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46(3):399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786","journal-title":"Multivariate Behav Res"},{"key":"4105_CR14","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.2147\/PPA.S110147","volume":"10","author":"J Mahlich","year":"2016","unstructured":"Mahlich J, Sruamsiri R (2016) Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan. Patient Prefer Adherence 10:1509\u20131519. https:\/\/doi.org\/10.2147\/PPA.S110147","journal-title":"Patient Prefer Adherence"},{"key":"4105_CR15","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.semarthrit.2016.09.005","volume":"46","author":"K Aaltonen","year":"2016","unstructured":"Aaltonen K, Heinonen A, Joensuu J, Parmanne P, Karjalainen A, Varjolahti-Lehtinen T, Uutela T, Puurtinen-Vilkki M, Arstila L, Blom M, Sokka T, Nordstrom D (2016) Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: a prospective cohort study. Semin Arthritis Rheum 46:732\u2013739. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.09.005","journal-title":"Semin Arthritis Rheum"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4105-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4105-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4105-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T00:59:20Z","timestamp":1660957160000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4105-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,18]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["4105"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4105-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,18]]},"assertion":[{"value":"18 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"BB is an independent statistician and medical writer who has consulted to a wide number of pharmaceutical companies, including AbbVie, Janssen-Cilag Pty Ltd., and Roche Products Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}